ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,930.85
      1.09%
      US Tech 100
      20,836.00
      1.31%
      Dow Jones
      42,840.26
      1.18%
      Brent Oil
      72.72
      0.00%
      Bitcoin
      96,736.51
      -0.48%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Arcellx Inc (ACLX)

      7. Arcellx Inc (ACLX) News

      Arcellx Inc

      Arcellx Inc (ACLX)

      NASDAQ
      75.54
      0.33
      (0.44%)
      Closed December 21 4:00PM
      Delayed by 15 minutes
      75.54
      -0.09
      (-0.12%)
      After Hours: 6:29PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      ACLX News

      Official News Only

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 09 2024
      ACLX (0.44%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      November 19 2024
      ACLX (0.44%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      November 14 2024
      ACLX (0.44%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      November 12 2024
      ACLX (0.44%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      November 08 2024
      ACLX (0.44%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 07 2024
      ACLX (0.44%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 07 2024
      ACLX (0.44%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 05 2024
      ACLX (0.44%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      October 22 2024
      ACLX (0.44%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      September 17 2024
      ACLX (0.44%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      September 17 2024
      ACLX (0.44%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      September 06 2024
      ACLX (0.44%)

      ACLX Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      ACLX under $100
      👍️0
      Monksdream Monksdream 3 months ago
      ACLX new 52 week high
      👍️0
      Monksdream Monksdream 5 months ago
      ACLX under $100
      👍️0
      Monksdream Monksdream 9 months ago
      ACLX over $30
      👍️0
      Monksdream Monksdream 11 months ago
      ACLX new 52 week high
      👍️0
      Monksdream Monksdream 11 months ago
      ACLX new 52 week high
      👍️0
      Monksdream Monksdream 11 months ago
      ACLX new 52 week high
      👍️0
      bandit007 bandit007 3 years ago
      Going beast mode into next week.
      👍️0
      TheyWantYourShares TheyWantYourShares 3 years ago
      Nice correction coming here. New IPO at 16… company is flush with capital/cash. Moves coming and getting in now will pay off big IMHO.


      Got in on the drop @average: 13.12 … 2 and 3 days ago.


      $ACLX


      GLTA!!



      -TWYS
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Net loss of $44M > no revenues! ( over 9 month period)

      ACLX
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share. With 33.54 million shares expected to be outstanding after the IPO, the expected pricing could value the company at up to $570.24 million. The stock is expected to list on the Nasdaq under the ticker symbol "ACLX." BofA Securities, SVB Leerink, Barclays and William Blair are the lead underwriters. The company recorded a net loss of $44.30 million on no revenue during the nine months ended Sept. 30, after a loss of $23.00 million on no revenue in the same period a year ago. Arcellx is looking to go public at a time of relative investor disdain for IPOs and biotechs, as the Renaissance IPO ETF IPO, -3.27% has plunged 37.2% over the past three months and the iShares Biotechnology ETF IBB, -1.39% has tumbled 19.8%, while the S&P 500 SPX, +0.31% has slipped 3.8%.
      👍️0

      Your Recent History

      NASDAQ
      ACLX
      Arcellx
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads